Panacea Biotech to produce 25 million doses of Sputnik V corona vaccine

Indian vaccine producer Panacea Biotech has signed a licensing deal for producing 25 million doses of the Sputnik V corona vaccine.

The company has entered into an agreement with Human Vaccine Limited Liability Company, a Russian Direct Investment Fund (RDIF) subsidiary, Generium Joint Stock Company, and Dr. Reddy’s Laboratories.

Under the terms of the agreement, Panacea Biotec will produce the Sputnik V corona vaccine with the ‘ready to fill’ drug substance manufactured by Generium in Russia. Subsequently, the Indian vaccine producer will deliver all the doses to Dr Reddy’s Laboratories for distributing them in India.

Russian Covid-19 vaccine Sputnik V. Photo courtesy of The Russian Direct Investment Fund.

Last month, Panacea Biotec was granted a manufacturing license from the Drugs Controller General of India (DCGI) for the Sputnik V vaccine. The company had been producing the Russian Covid vaccine since May 2021.

A month earlier in April, RDIF and Panacea Biotec announced that they will produce 100 million doses per year of the Sputnik V Covid vaccine in India.

COVID-19, Dr. Reddy’s Laboratories, Generium Joint Stock Company, Human Vaccine Limited Liability Company, India, Panacea Biotec, Russian Direct Investment Fund, Sputnik V vaccine